
-

FDA Funds Study of Real World Data for Biosimilars
A group of managed care organizations is examining the value of real world data from Europe and the U.S. to help FDA review alternative biologic drugs.
-

Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-

Infographic – Global Q3 Venture Funding Levels Off
Global venture investment dollars in the third quarter of 2023 rose somewhat from the previous quarter, but remained at about the same level for the past 12 months.
-

NIH Funds Antibody Discovery for Difficult Protein Targets
A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.
-

Vaccine Shown to Protect Against Multiple Hospital Pathogens
Research with lab mice shows an experimental vaccine stimulates the body’s basic immune system to protect against a range of pathogens associated with hospital infections.
-

Biomanufacturing Company Gains $9.5M in Early Funds
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round.
-

Industry-Academic Center to Boost Rare Disease Therapies
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K.
-

FDA Clears Genetic Cancer Risk Detection Test
The Food and Drug Administration authorized marketing of a genetic test for detecting hundreds of gene variants associated with a higher risk of developing certain cancers.
-

Infographic – Biotech Index Continues Downward Trend
The Nasdaq Biotechnology Index, an indicator of investor sentiment in an industry based on science, continued heading down during the third quarter of 2023.
-

Biotech Thymus Tissue Process Gains ARPA-H Funding
A company with a process to generate new thymus tissue for immune system functions is receiving a $37 million award from the government’s health breakthrough agency.